Effect of TTP488 in patients with mild to moderate Alzheimer's disease

Effect of TTP488 in patients with mild to moderate Alzheimer's disease

BACKGROUND:TTP488, an antagonist at the Receptor for Advanced Glycation End products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD). A previous report describes decreased decline in ADAS-cog (delta=3.1, p=0.008 at 18 months, ANCOVA with multi...

Full description

Bibliographic Details
Main Authors: Burstein, Aaron, Grimes, Imogene, Galasko, Douglas, Aisen, Paul, Sabbagh, Marwan, Mjalli, Adnan
Other Authors: TransTech Pharma, High Point, NC, USA
Language:en
Published: BioMed Central 2014
Online Access:Burstein et al. BMC Neurology 2014, 14:12 http://www.biomedcentral.com/1471-2377/14/12
http://hdl.handle.net/10150/610067
http://arizona.openrepository.com/arizona/handle/10150/610067

Internet

Burstein et al. BMC Neurology 2014, 14:12 http://www.biomedcentral.com/1471-2377/14/12
http://hdl.handle.net/10150/610067
http://arizona.openrepository.com/arizona/handle/10150/610067

Similar Items